English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 908197      Online Users : 936
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/9560


    Title: The International SSRI Pharmacogenomics Consortium (ISPC): A genome-wide association study of antidepressant treatment response
    Authors: Biernacka, JM;Sangkuhl, K;Jenkins, G;Whaley, RM;Barman, P;Batzler, A;Altman, RB;Arolt, V;Brockmoller, J;Chen, CH;Domschke, K;Hall-Flavin, DK;Hong, CJ;Illi, A;Ji, Y;Kampman, O;Kinoshita, T;Leinonen, E;Liou, YJ;Mushiroda, T;Nonen, S;Skime, MK;Wang, L;Baune, BT;Kato, M;Liu, YL;Praphanphoj, V;Stingl, JC;Tsai, SJ;Kubo, M;Klein, TE;Weinshilboum, R
    Contributors: Center for Neuropsychiatric Research
    Abstract: Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects from seven sites. The primary outcomes were percent change in HRSD-17 score and response, defined as at least 50% reduction in HRSD-17. Data from two prior studies, the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study (PGRN-AMPS) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, were used for replication, and a meta-analysis of the three studies was performed (N = 2394). Although many top association signals in the ISPC analysis map to interesting candidate genes, none were significant at the genome-wide level and the associations were not replicated using PGRN-AMPS and STAR*D data. Top association results in the meta-analysis of response included single-nucleotide polymorphisms (SNPs) in the HPRTP4 (hypoxanthine phosphoribosyltransferase pseudogene 4)/VSTM5 (V-set and transmembrane domain containing 5) region, which approached genome-wide significance (P = 5.03E - 08) and SNPs 5' upstream of the neuregulin-1 gene, NRG1 (P = 1.20E - 06). NRG1 is involved in many aspects of brain development, including neuronal maturation and variations in this gene have been shown to be associated with increased risk for mental disorders, particularly schizophrenia. Replication and functional studies of these findings are warranted.
    Date: 2015-04
    Relation: Translational Psychiatry. 2015 Apr;5(4):Article number e553.
    Link to: http://dx.doi.org/10.1038/tp.2015.47
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2158-3188&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000367655600002
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84990909819
    Appears in Collections:[劉玉麗] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI000367655600002.pdf1751KbAdobe PDF403View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback